Janus Henderson Group PLC Sells 883,730 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Janus Henderson Group PLC trimmed its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 96.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,811 shares of the medical device company's stock after selling 883,730 shares during the quarter. Janus Henderson Group PLC's holdings in Tandem Diabetes Care were worth $1,074,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Arizona State Retirement System raised its holdings in Tandem Diabetes Care by 1.9% in the 4th quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock valued at $683,000 after acquiring an additional 362 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Tandem Diabetes Care by 4.3% during the 4th quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock worth $360,000 after acquiring an additional 409 shares during the period. Summit Investment Advisors Inc. lifted its holdings in shares of Tandem Diabetes Care by 8.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company's stock worth $247,000 after acquiring an additional 525 shares during the period. Assetmark Inc. boosted its position in shares of Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after acquiring an additional 535 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares during the period.

Tandem Diabetes Care Price Performance

Shares of TNDM traded up $0.13 on Thursday, hitting $21.28. The company's stock had a trading volume of 1,684,227 shares, compared to its average volume of 1,490,974. The company has a market capitalization of $1.42 billion, a PE ratio of -11.03 and a beta of 1.47. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69. The company has a 50 day moving average price of $19.44 and a 200 day moving average price of $27.20. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. During the same period in the prior year, the company earned ($0.65) EPS. The firm's revenue was up 22.3% compared to the same quarter last year. On average, research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TNDM shares. Robert W. Baird reduced their price objective on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. Citigroup raised their price target on shares of Tandem Diabetes Care from $20.00 to $24.00 and gave the company a "neutral" rating in a report on Thursday, May 22nd. Stifel Nicolaus reduced their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Mizuho started coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Finally, Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $45.00 to $22.00 in a research note on Wednesday, March 5th. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and a consensus price target of $37.47.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.